Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (271-280 of 596) with videos related to

Pageof 60
Sort By:
Pharmacotherapy|November 13, 2004
Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapyJoseph L Kuti, Kerry M Moss, David P Nicolau, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2009
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosaJared L Crandon, Catharine C Bulik, Joseph L Kuti, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2018
Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an <i>In Vitro</i> Pharmacodynamic ModelVeronica Rico Caballero, Safa Almarzoky Abuhussain, Joseph L Kuti, et al.
Connecticut Medicine|July 30, 2009
Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospitalJoseph L Kuti, Anthony M Nicasio, Christina A Sutherland, et al.
Paediatric Drugs|November 13, 2008
Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in childrenMichael E Pichichero, Gary V Doern, Joseph L Kuti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2014
Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemesNathaniel J Rhodes, Shawn H MacVane, Joseph L Kuti, et al.
Nigerian Journal of Medicine : Journal of the National Association of Resident Doctors of Nigeria|June 25, 2014
Pattern of placenta histopathology in low birth weight babies seen in a tertiary health centre in South-Western NigeriaG O Omoniyi-Esan, O O Olaofe, A E Omonisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2024
Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosaAndrew J Fratoni, Matthew L Gethers, David P Nicolau, et al.
Infection Control and Hospital Epidemiology|April 14, 2016
The Essential Role of Pharmacists in Antimicrobial StewardshipEmily L Heil, Joseph L Kuti, David T Bearden, et al.
The Journal of Antimicrobial Chemotherapy|December 3, 2004
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in EuropeRobert G Masterton, Joseph L Kuti, Philip J Turner, et al.
Pageof 60

Showing results (271-280 of 596) with videos related to

Sort By:
Pageof 60
Pharmacotherapy|November 13, 2004
Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapyJoseph L Kuti, Kerry M Moss, David P Nicolau, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2009
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosaJared L Crandon, Catharine C Bulik, Joseph L Kuti, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2018
Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an <i>In Vitro</i> Pharmacodynamic ModelVeronica Rico Caballero, Safa Almarzoky Abuhussain, Joseph L Kuti, et al.
Connecticut Medicine|July 30, 2009
Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospitalJoseph L Kuti, Anthony M Nicasio, Christina A Sutherland, et al.
Paediatric Drugs|November 13, 2008
Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in childrenMichael E Pichichero, Gary V Doern, Joseph L Kuti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2014
Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemesNathaniel J Rhodes, Shawn H MacVane, Joseph L Kuti, et al.
Nigerian Journal of Medicine : Journal of the National Association of Resident Doctors of Nigeria|June 25, 2014
Pattern of placenta histopathology in low birth weight babies seen in a tertiary health centre in South-Western NigeriaG O Omoniyi-Esan, O O Olaofe, A E Omonisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2024
Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosaAndrew J Fratoni, Matthew L Gethers, David P Nicolau, et al.
Infection Control and Hospital Epidemiology|April 14, 2016
The Essential Role of Pharmacists in Antimicrobial StewardshipEmily L Heil, Joseph L Kuti, David T Bearden, et al.
The Journal of Antimicrobial Chemotherapy|December 3, 2004
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in EuropeRobert G Masterton, Joseph L Kuti, Philip J Turner, et al.
Pageof 60